UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era

Journal of clinical oncology, 2012-09, Vol.30 (27), p.3383-3388

2012

Volltextzugriff (PDF)

The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association

Clinical cancer research, 2015-08, Vol.21 (15), p.3428-3435

2015

Volltextzugriff (PDF)

Incidence, risk factors and outcome of histological transformation in follicular lymphoma

British journal of haematology, 2012-04, Vol.157 (2), p.188-196

2012

Volltextzugriff (PDF)

Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma

Leukemia & lymphoma, 2017-02, Vol.58 (2), p.324-332

2017

Volltextzugriff (PDF)

Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma

Blood, 2019-08, Vol.134 (9), p.761-764

2019

Volltextzugriff (PDF)

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

The lancet oncology, 2015-09, Vol.16 (9), p.1111-1122

2015

Volltextzugriff (PDF)

Curing diffuse large B-cell lymphomas in elderly patients

European journal of internal medicine, 2018-12, Vol.58, p.14-21

2018

Volltextzugriff (PDF)

Late relapse in patients with diffuse large B‐cell lymphoma: impact of rituximab on their incidence and outcome

British journal of haematology, 2019-11, Vol.187 (4), p.478-487

2019

Volltextzugriff (PDF)

Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?

Leukemia & lymphoma, 2017-01, Vol.58 (1), p.30-36

2017

Volltextzugriff (PDF)

Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy

Journal of clinical oncology, 2021-01, Vol.39 (2), p.107-115

2021

Volltextzugriff (PDF)

SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model

Blood advances, 2020-03, Vol.4 (6), p.1082-1092

2020

Volltextzugriff (PDF)

Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines

Blood advances, 2021-03, Vol.5 (5), p.1483-1489

2021

Volltextzugriff (PDF)

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma

Blood advances, 2022-07, Vol.6 (13), p.3911-3920

2022

Volltextzugriff (PDF)

Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

Blood advances, 2020-12, Vol.4 (23), p.5951-5957

2020

Volltextzugriff (PDF)

Outcome of patients older than 80 years with diffuse large B‐cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions

Hematological oncology, 2018-02, Vol.36 (1), p.84-92

2018

Volltextzugriff (PDF)

Managing newly diagnosed follicular lymphoma: state of the art and future perspectives

Expert review of anticancer therapy, 2013-03, Vol.13 (3), p.313-325

2013

Volltextzugriff (PDF)

Follicular Lymphoma

Indolent Lymphomas, p.67-91

Volltextzugriff (PDF)

Transformation of follicular lymphoma in the era of immunochemotherapy: A population-based study from British Columbia

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.8049-8049

2012

Volltextzugriff (PDF)

Tumor-Associated Macrophages Predict Outcome in Follicular Lymphoma

Blood, 2012-11, Vol.120 (21), p.682-682

2012

Volltextzugriff (PDF)

Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment

Blood, 2010-11, Vol.116 (21), p.1751-1751

2010

Volltextzugriff (PDF)

Front-Line Therapy with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance

Blood, 2010-11, Vol.116 (21), p.1803-1803

2010

Volltextzugriff (PDF)

Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)

Blood, 2010-11, Vol.116 (21), p.113-113

2010

Volltextzugriff (PDF)

R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines

Blood, 2009-11, Vol.114 (22), p.408-408

2009

Volltextzugriff (PDF)

Follikuläres Lymphom

Indolente Lymphome, p.75-102

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(48)
Buchkapitel
(2)

Sprache

Englisch
(49)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Humans
(24)
Hematology
(16)
Female
(12)
Lymphoma
(12)
Oncology
(12)
Chemotherapy
(11)
Male
(11)
Aged
(10)
Middle Aged
(10)
Treatment Outcome
(10)
Adult
(9)
Rituximab
(9)
Hodgkin Disease - Drug Therapy
(8)
Lymphoma, Follicular - Drug Therapy
(8)
Doxorubicin
(7)
Prognosis
(7)
Survival
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma

International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era

The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association

Incidence, risk factors and outcome of histological transformation in follicular lymphoma

Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma

Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Curing diffuse large B-cell lymphomas in elderly patients

Late relapse in patients with diffuse large B‐cell lymphoma: impact of rituximab on their incidence and outcome

Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?

Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy

SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model

Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma

Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

Outcome of patients older than 80 years with diffuse large B‐cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions

Managing newly diagnosed follicular lymphoma: state of the art and future perspectives

Follicular Lymphoma

Transformation of follicular lymphoma in the era of immunochemotherapy: A population-based study from British Columbia

Tumor-Associated Macrophages Predict Outcome in Follicular Lymphoma

Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment

Front-Line Therapy with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance

Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)

R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines

Follikuläres Lymphom

Suchergebnisse filtern